Loading

Exeliom Biosciences

June 04, 2024
Company Presentation
Inflammation
Company Presentation Theater 3
Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation immunotherapies in immuno-oncology and immuno-inflammation. EXL01 – our lead drug candidate - is a first-in-class oral drug with a novel mechanism of action that demonstrates enhanced activation of key regulators of the innate immune system. Thanks to a robust and scalable manufacturing process EXL01 is being evaluated in 6 clinical trials, including: - A phase I trial, as monotherapy, in Crohn's (recruitment completed), - Three phase II trials, as combination therapy, in immuno-oncology in combination with immune checkpoint inhibitors (2 ongoing and 1 to start end of 2024), - A phase I/II trial in the prevention of recurrent C. difficile infection (ongoing). - An additional Phase II trial, as monotherapy and combination therapy, in postoperative Crohn's disease is due to start late 2024.
Exeliom Biosciences
Company Website: http://www.exeliombio.com
Lead Product in Development: Exl01, a next generation immunomodulator targeting the innate immune system with applications in IBD, Immuno-oncology and infectious diseases.
Number Of Unlicensed Products (For Which You Are Seeking Partners): 2

Company HQ City

Paris

Company HQ State

France

Company HQ Country

France

CEO/Top Company Official

Benjamin Hadida

Development Phase of Primary Product

Phase II
Speakers
Benjamin Hadida
CEO
Exeliom Biosciences
Back to Session List

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS